D2.43 - Implementation of the New Italian Health Care Price List: Impact on Allergy Diagnostics

In Italy, a new reimbursement framework for healthcare services came into force on December 30, 2024. This revision includes updated and novel codes for allergy diagnostics, notably specific IgE tests. The decentralized nature of the Italian healthcare system allows regional authorities to adapt the implementation of these changes, leading to variability in accessibility. This study aims to assess the potential impact of the new framework on allergy test utilization and to explore its alignment with clinical needs.

We analyzed the updates to the reimbursement codes and examined their practical implications for allergy diagnostics across various Italian regions. Key areas of focus included the availability of advanced diagnostic tests, the feasibility of new prescribing methods, and their compliance with guidelines from scientific societies. Special attention was given to the introduction of multiplex tests, second-level diagnostics, and third-level investigations.

Preliminary analysis revealed significant regional disparities in the regulation and accessibility of specific IgE tests. In certain regions, clinicians were previously allowed to prescribe numerous tests without strict limitations, while in others, key tests—such as molecular components, Tryptase, and Eosinophil Cationic Protein (ECP)—were unavailable due to reimbursement constraints. The revised framework addresses these issues by enabling reimbursement for singleplex molecular components and advanced tests like multiplex panels. These innovations support the use of second-level diagnostics to refine diagnoses and introduce third-level investigations, such as CAP-inhibition tests, for complex cases. Additionally, tests like Tryptase and ECP, previously limited to the private sector, are now reimbursed, ensuring broader access.

The updated reimbursement system has the potential to enhance diagnostic precision and promote appropriate use of allergy tests. By providing regulated access to advanced diagnostic tools and aligning with clinical guidelines, these changes may foster greater confidence in specific IgE testing among clinicians, ultimately improving patient outcomes.